

# Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences

## Abstract

The Pan-cancer Analysis of Whole Genomes (PCAWG) project provides an unprecedented opportunity to comprehensively characterize a vast set of uniformly annotated coding and non-coding mutations present in thousands of cancer genomes. Classical models of cancer progression posit that only a small number of these mutations strongly drive tumor progression and that the remaining ones (termed “*putative passengers*”) are inconsequential for tumorigenesis. In this study, we leveraged the comprehensive variant data from PCAWG to ascertain the molecular functional impact of each variant, including *putative passengers*. The predicted functional impact distribution of PCAWG mutations shows that, in addition to high- and low-impact mutations, there is a group of medium-impact *putative passengers* predicted to influence gene expression or activity. Moreover, we found that predicted functional impact relates to the underlying mutational signature: different signatures confer divergent impact, differentially affecting distinct regulatory subsystems and categories of genes. Additionally, we find that functional impact varies based on subclonal architecture (i.e., early vs. late mutations) and can be related to patient survival. Finally, we note that insufficient power due to limitation in cohort sizes precludes identification of weak drivers using standard recurrence-based approaches. To address this, we adapted an additive effects model derived from complex trait studies to show that aggregating *putative passenger* variants (i.e. including weak drivers) provides significant predictability for cancer phenotypes beyond the characterized driver mutations. This framework allowed us to estimate the frequency of potential weak driver mutations in the subset of PCAWG samples that lack well characterized driver alterations.

## **Introduction**

Previous studies have focused on characterizing variants within coding regions of cancer genomes<sup>1</sup>. However, the extensive Pan-cancer Analysis of Whole Genomes (PCAWG) dataset<sup>2</sup>, which includes variant calls from more than 2500 uniformly processed whole-cancer genomes, offers an unparalleled opportunity to investigate the overall molecular functional impact of variants influencing both coding and non-coding genomic elements. Given that the majority of cancer variants lie in non-coding regions<sup>3</sup>, this variant dataset serves as a substantially more informative resource than the many existing datasets focused on exomes. Moreover, it also contains a full spectrum of variants, including somatic copy number alterations (SCNAs) and large structural variants (SVs), in addition to single-nucleotide variants (SNVs) and small insertions and deletions (INDELs).

Of the 30 million SNVs in the PCAWG variant data set, several thousand (less than 5/tumor<sup>4</sup>) are identified as driver variants (i.e., positively selected variants that favor tumor growth) by recurrence-based driver detection methods. The remaining ~99% of SNVs are termed passenger variants (referred to as *putative passengers* in this work), with poorly understood molecular consequences and fitness effects. Recent studies have proposed that, among *putative passengers*, some may weakly affect tumor cell fitness by promoting or inhibiting tumor growth. In prior studies, these variants have been described as “mini-drivers”<sup>5</sup> and “deleterious passengers”<sup>6</sup>, respectively.

In this work, we explored the landscape of *putative passengers* in various cancer cohorts by leveraging uniformly generated extensive pan-cancer variant calls<sup>7,8</sup>, driver mutation catalog<sup>9</sup>, transcriptome profile<sup>10</sup>, mutational signatures [cite pcawg7] and subclonal status [cite pcawg11] of more than 2500 samples generated as part of PCAWG. Additionally, the driver discovery exercise in PCAWG suggests absence of driver events in few PCAWG samples despite large number of non-coding alterations. Thus, we closely inspected cumulative effect of *putative passengers* in PCAWG samples. More specifically, we built on and applied existing tools to annotate and score the predicted molecular functional impacts of variants in the pan-cancer dataset. This systematic annotation and impact prediction effort generated an exhaustive compendium of PCAWG variants, thereby providing a valuable resource. Furthermore, we integrated the annotation and impact score of each variant to quantify the overall burdening of various genomic elements in different cancer cohorts. We observed that disruption of genetic

regulatory elements in non-coding elements correlates with altered gene expression. Moreover, as elucidated by our signature analysis, various mutational processes have differential impacts on coding genes and regulatory elements. We found that the molecular functional impact burden of various genomic elements correlates with patient survival time and tumor clonality. We also observed differential impacts of *putative passengers* that may impact tumor progression. However, these *putative passenger* mutations may be driven purely by background processes or may suggest non-neutral effects. Hence, we also considered ways of assessing possible non-neutral roles for *putative passengers*.

We found that *putative passengers* provide significant predictive power (beyond common driver mutations) to distinguish cancer from non-cancer phenotypes, even after controlling for known mutational signatures and background mutation rates as possible confounders. We determined that this effect is likely prominent among tumors without known drivers, or with fewer driver variants than expected. Although the effects of these possible driver variants can only be detected in aggregate by our model, it motivates future searches for these variants among *putative passengers*, especially within in non-coding regions of the genome. Finally, we note that selection acting on somatic cells is dynamic in nature. Thus, *putative passengers* may act as driver mutations at some later phase during tumor progression, when treatment is given or the clone spreads to another organ. Therefore, it is valuable to characterize *putative passengers*, even if their predicted functional effects are not of selective consequence currently.

### **Overall molecular functional impact**

In order to characterize the landscape of *putative passenger* mutations in PCAWG, we first surveyed the predicted molecular functional impact (quantified by funseq score<sup>11</sup>) of somatic variants in different cancer genomes. The predicted functional impact distribution varies among different cancer types and for different genomic elements. A closer inspection of the pan-cancer impact score distributions for non-coding variants demonstrated three distinct regions. The upper and the lower extremes of this distribution are presumably enriched with high-impact strong drivers and low-impact neutral passengers, respectively. In contrast, the middle range of this distribution corresponds to *putative passengers* with intermediate molecular functional impact (**Fig 1a**).

Subsequently, we investigated whether the frequency of medium- and high-impact noncoding *putative passengers* (see **supplement section 1.4** for classification threshold) in a cancer cohort is proportionate to its total mutational burden. For a uniform mutation distribution, we expect that the fraction of these *putative passengers* would remain constant as cancer samples accumulate more mutations. In contrast, we observed that as a tumor acquires more SNVs, the fraction of medium- and high-impact *putative passengers* often decreases. This trend is particularly strong in CNS medulloblastoma ( $p < 4e-8$ ), lung adenocarcinoma ( $p < 3e-4$ ), and a few other cancer cohorts (**Fig 1b & supplement Fig. S4**).

In addition to SNVs, large structural variations (SVs) also play an important role in cancer progression. Thus, we quantified the putative functional impact of SVs (deletions and duplications). A close inspection of both SV and SNV impact scores suggest that certain cancer subtypes tend to harbor a large number of high-impact SVs, while others were more burdened with high-impact SNVs (**Fig 1c**). Many of these correlations have previously been observed<sup>12</sup>. For example, it is known that large deletions play the role of drivers in ovarian cancer, whereas clear cell kidney cancer is often driven by SNVs. However, we also find new associations, such as the predominance of high-impact large deletions compared to impactful SNVs in the bone leiomyoma cohort. Similarly, a close inspection of high impact large duplication and high impact SNVs suggest their differential activity toward different cancer cohorts (see **supplement Fig. S5**).

### **Burdening of different genomic elements**

Furthermore, we investigated the overall mutational burden observed among different genomic elements in various cancer cohorts. *A priori*, one might assume that the overall burden of *putative passengers* in a cancer genome would be uniformly distributed across different functional elements and among different gene categories. In contrast, we observed that the predicted molecular impact burden in certain cancers is concentrated in particular regulatory regions and gene categories. This is easiest to understand in terms of coding loss-of-function variants (LoFs), where the putative molecular impact is most intuitive. We thus examined the fraction of deleterious LoFs affecting genes across seven categories of cancer-related functional annotation (**Fig 2a & supplement Fig. S6-S7**). Driver LoF variants showed significant overlap with six categories of cancer-related genes (cell cycle, immune response, cancer pathway,

apoptosis, DNA repair and essential genes) relative to a genome-wide expectation ( $p < 0.001$ ). Conversely, non-driver LoFs displayed a small but significant depletion relative to a genome-wide expectation in each of these categories except in metabolic and immune response genes, for which they showed slight enrichment compared to the genome-wide expectation ( $p < 0.001$ ). We note the possibility that differential tendency towards mutation or mutation repair among these gene categories may contribute to these observations (e.g. higher expression among essential genes may lead to both increased transcription-coupled damage and transcription-coupled repair).

As with LoF variants, we can also quantify the overall burden of the noncoding SNVs in a cancer genome. However, for the majority of noncoding SNVs, predicted molecular functional impact is less easy to gauge. For instance, coding and noncoding variants occupying the terminal region of the gene or intronic regions would most likely have little functional consequence. In contrast, the molecular functional impact of transcription factor binding site (TFBS) variant is clearly manifested through the creation or destruction of transcription factor (TF) binding motif (gain or loss of motif). In both cases (gain or loss), we observed significant differential burdening of TFBS among different cancer cohorts. For instance, we detected significant enrichment of high-impact variants creating new motifs in various TFs including GATA, PRRX2 and SOX10 (**Fig 2b & supplement Fig. S8-S9**) across major cancer types, compared with genome-wide expectation. Similarly, high-impact variants breaking motifs were highly enriched in TFs such as IRF, POU2F2, NR3C1 and STAT (**Fig 2b & supplement Fig. S8-S9**) in the majority of cohorts. This selective enrichment or depletion suggests distinct alteration profiles associated with different components of regulatory networks in various cancers.

Furthermore, for a particular TF family, one can identify the associated target genes affected due to the bias towards creation or disruption of specific motifs in their regulatory elements (promoters and enhancers). For instance, the TERT gene shows the largest alteration bias for ETS motif creation across a variety of cancer types (**Fig 2c & supplement Fig. S10-S11**). Other genes (such as BCL6) showed a similar bias, albeit in fewer cancers. Moreover, the enrichment of SNVs in selective TF motifs leads to gain and break events in promoters that significantly perturb the overall downstream gene expression (**Fig 2d & supplement Fig. S10-S12**). For example, ETS family transcription factor at the regulatory region of TERT and BCL2 gene displayed a strong motif creation bias and a significant change in gene expression (with p-

value TERT=5.49e-5 and p-value BCL2=3.4e-4). Similarly, while aggregating expression of all downstream genes affected by the same TF motif change, we found several motif events are highly significant (**supplement Fig. S13-14**). For instance, motif gain in ZBTB14 and E2F in lung adenocarcinoma, ETS motif gain in thyroid adenocarcinoma and TFAP2E and TFAP motif loss in lymphoma.

Finally, we also analyzed the overall burden of structural variants (SVs) in various genomic elements and compared the pattern of somatic SV (large deletions and duplications) enrichment in cancer genomes with those from the germline (**Fig 2e**). As expected, we observed that somatic SVs were more enriched among functional regions compared to germline SVs, because the latter ones will be under negative selection for disrupting functional regions (**Fig 2e & supplement Fig. S15**). Furthermore, we observed a distinct pattern of enrichment for SVs that split a functional element versus those that engulf it. As has been previously noted, there is a greater enrichment of germline SVs that engulf an entire functional element rather than for those that break a functional element partially<sup>13</sup>. Interestingly, we observed the same pattern among somatic SVs (**Fig 2e & supplement Fig. S15**).

### **Mutational processes analysis**

The differential burdening of various genomic elements may be attributed to an underlying stochastic but biased mutational processes. Thus, we closely inspected the underlying mutational processes generating SNVs in both coding and non-coding regions of cancer genomes. First, we looked into the most impactful event, loss-of-function mutations in coding regions. We would anticipate premature stop codons to show strong mutational contextual bias due to the nature of codon composition. Indeed, we found premature stop mutations carry a specific mutational spectrum, which differs significantly from the overall tumor mutational spectrum. In particular, some mutations (e.g. T>Cs) cannot create premature stop as we expected. However, when compared with the pan-cancer premature stops, individual cancer shows a spectrum shift. For example, premature stops in RCCs (renal cell carcinomas) show a higher percentage of T>As compared to all cancers (18% versus 8%) (**Fig 3a**). Our observation can be explained by the divergence of mutational processes in individual cancer types and implies mutational processes confer distinct effects in coding regions.

Similarly, the disproportionate functional load on certain TFs in cancers can be related to the underlying mutational spectrum influencing their binding sites. Different transcription factors have varying nucleotide context in their binding sites (TFBS). These variations may facilitate the role of different mutational processes and will be reflected in their mutational spectrum. For instance, the mutational spectrum of motif breaking events observed in SP1 TFBS suggests a major contribution from C>T and C>A mutations (**Fig 3a**). In contrast, motif-breaking events at the TFBS of HDAC2 and EWSR1 have relatively uniform mutational spectrum profiles.

Based on the mutational context, we can further decompose all observed mutations into a linear combination of mutational signatures, which presumably represent the mutational processes<sup>14,15</sup>. Every signature (cite pcast7) has varying influence depending on the cancer type and in a given cancer type, different signatures disproportionately burden the genome. Comparing the signature composition of low-and high-impact *putative passengers* in certain cancer-cohorts can help us to distinguish between mutational processes that generate distinct variant impact classes. For instance, in the chRCC (chromophobe renal cell carcinoma) cohort, although the majority of *putative passenger* variants can be explained by signature 39, high-impact and low-impact *putative passengers* have a different proportion of signature 5 and signature 1 (**Fig 3b**). We also scrutinized LoFs in coding regions, which carry the highest molecular function impact. Compared to noncoding *putative passengers*, signature 1 and 23 together contribute a relatively higher fraction to premature stops. We further generalized this analysis across multiple cohorts in PCAWG. Similar to Kidney-chRCC cohort, we observed distinct signature distributions for the low-and high-impact non-coding *putative passengers* in Liver-HCC, Prost-AdenoCA, Eso-AdenoCA and Ovary-AdenoCA cohorts (**Fig 3c**). In addition to mutational signatures, we observed that cancer samples with microsatellite instability (MSI) due to failure of DNA mismatch repair, have higher percentage of high impact non-coding *putative passengers* (**supplement Fig. S16**). Collectively, these findings suggest that various mutational processes shape and disproportionately burden cancer genomes.

### **Subclonal architecture and cancer progression**

Cancer is an evolutionary process, often characterized by the presence of different sub-clones. These can be further categorized as early and late subclones based on the overall subclonal architecture of a cancer sample. Thus, we explored the relative population of high- and low-

impact *putative passengers* in different sub-clones of a tumor sample (cite p11) to decipher their progression during tumor evolution. Intuitively, one might hypothesize that high-impact mutations achieve greater prevalence in tumor cells if they are advantageous to the tumor, and a lower prevalence if deleterious. As expected, we observe this to be true among driver variants. However, interestingly, we observe that high-impact *putative passengers* in coding regions have greater prevalence among parental subclones (**Fig 4a**) – an effect driven by high-impact *putative passenger* SNVs in tumor suppressor and apoptotic genes (**Fig 4a**). In contrast, high-impact *putative passenger* SNVs in oncogenes appear slightly depleted in parental subclones. Similarly, high-impact *putative passengers* in DNA repair genes and cell cycle genes are depleted in early subclones (**Fig 4a**). We obtained similar results when we simply categorized mutations on the basis of variant allele frequency (VAF) (**supplement Fig. S17**).

In non-rearranged genomic intervals, the VAF of a mutation is expected to be proportional to the fraction of tumor cells bearing that mutation. Previous studies<sup>16</sup> have measured the divergence in VAFs to indirectly quantify heterogeneity in mutational burden among different sub-clones in a cancer. Here, we quantified this heterogeneity among low-, medium- and high-impact *putative passengers* for different cancer cohorts (see **supplement section 6.2**). We generally observe lower mutational heterogeneity among high-impact *putative passenger* SNVs. This observation is consistent for both coding and non-coding *putative passenger* variants (**Fig 4b**).

Furthermore, we correlated the molecular functional impact (measured by GERP score here) of each variant with their corresponding cellular prevalence measured by VAF (see **supplement section 6.3**). We find that, within driver genes and their regulators, variants that disrupt more conserved positions (high GERP score) tend to have higher VAF values (**Fig 4c**). This trend remains true even after excluding SNVs that have been individually called as driver variants, suggesting that within driver genes, yet-uncalled driver variants remain. We also find that outside of driver genes, variants that disrupt more conserved positions tend to have lower VAF values (**Supplement Table 1**).

As with the clonal status of a tumor, clinical outcomes (such as patient survival) provide an alternative measure of tumor evolution. Therefore, we performed survival analysis to see if somatic molecular impact burden – here measured as the mean GERP of *putative passenger* mutations per patient – predicted patient survival within individual cancer subtypes. Patient age



at diagnosis was used as a covariate in the survival analysis. We obtained significant correlations between somatic molecular impact burden and patient survival in two cancer subtypes after multiple test correction (**Supplement Table 2**). Specifically, we observed that somatic molecular impact burden predicted substantially better patient survival in lymphocytic leukemia (Lymph-CLL, p-value  $2.3e-4$ ) and ovary adenocarcinoma (Ovary-AdenoCA, p-value  $2e-3$ ) (**Fig 4d**). The use of *average* impact rather than summed impact ensures that these results do not simply reflect more advanced progression (i.e. more mutations) of the cancer at the time of sequencing.

### **Categorizing putative passenger variants**

The comprehensive characterization of *putative passenger* landscape in PCAWG highlight many key attributes of *putative passengers*. The results we have found may be explained in relation to underlying mutational processes. However, they may also be indicative of selective effects among subset of these mutations, whether or not they are generated by a neutral mutational process. If indeed a subset of *putative passengers* possess fitness effects, then we can extend the canonical model of driver and passengers into a continuum model. Conceptually, in such extended model, somatic variants can be classified into multiple categories while considering their impact on tumor cell fitness: drivers with strong positive selective effects, *putative passengers* with neutral, weak positive and weak negative selective effects. This broad classification scheme can be further refined by considering ascertainment-bias and the putative molecular functional impact of different variants (**Fig 5a**). Previous power analyses<sup>17,18</sup> suggest that existing cohort sizes support the identification of strong positively-selected driver variants, but that many weaker drivers and even some moderately strong driver variants would be missed.

However, these moderately strong and weak driver variants can also provide a potential fitness advantage to tumor cells. With respect to the functional-impact-based classification, any positively or negatively selected variants will have some molecular functional impact (i.e. effect on gene expression or activity). The relevance of molecular functional impact is firmly established for driver mutations, defined as positively-selected variants promoting tumor growth. However, rapid accumulation of *putative passengers*, which undergo weak/strong negative selection, could adversely affect the fitness of tumor cells<sup>6</sup>. Moreover, a majority of low-impact and some high-functional impact *putative passengers* may alter tumor gene expression or activity

in ways that are not ultimately relevant for tumor fitness; hence, these variants will undergo neutral evolution.

An initial step towards identifying the presence of variants with effects on tumor fitness is to compare observed mutation distributions with ones generated by simulating or modeling neutral processes. This approach has been extensively leveraged in the context of individual driver discovery using element burden testing. Such an approach is potentially powerful since it allows the use of complex background mutational models, although the possibility of detecting artifacts due to the inadequacy of current models of neutral mutational processes remains, since unmodeled mutation process may result in confounding effects. With this caveat, we explore such an approach below in an attempt to quantify non-neutral aggregate effects among *putative passengers*, using a variety of background models and an additive effect model which combines both positive and negative fitness effects. As in the case of individual driver discovery, validation of such effects requires follow-up experimentation.

### **Overall effects of putative passengers and additive variance**

It is interesting to note that in a cancer genome, the presence of few drivers (with high positive fitness effects) and large numbers of *putative passengers* (with weak or neutral fitness effects) could be considered analogous to prior observations in genome-wide association studies (GWAS) that implicated a handful of variants influencing complex traits. These modest numbers of variants explain only a small proportion of the genetic variance, thus contributing to the “missing heritability” problem in GWAS<sup>19,20</sup>. However, it has been shown that aggregating the remaining variants with weak effects can explain a significant part of the “missing heritability”<sup>19</sup> and is predictive of phenotype<sup>21</sup>. We do not currently have estimates of “missing heritability” at the subclone level for tumorigenicity, which may depend on both genetic and epigenetic factors. However, the fact that some tumors in PCAWG (~10% of PCAWG samples) lack a known driver<sup>22</sup> suggests that some driver mutations remain to be discovered. The models above suggest the importance of investigating the cumulative effect of *putative passengers* in this context.

To address this, we adapted an additive effects model<sup>19,23</sup>, originally used in complex trait analysis, to quantify the relative size of the aggregated effect of *putative passengers* in relation to known drivers. With a number of caveats regarding interpretation arising due to differences between germline and cancer evolutionary processes (see **supplemental section 8**), we tested the

ability of this model to predict cancerous from null samples as a binary phenotypic trait (**Fig 5b**). Briefly, we created a balanced dataset of observed tumor and matched neutral (null) model samples, using a recently proposed background model which preserves mutational signatures, local mutation rates, and coverage bias (see **supplemental section 1.1.b**). Subsequently, using a linear model, for each SNV the additive effects model implicitly associates a positive or negative effect (coefficient), considering them to be sampled from a normal distribution (see **supplemental section 8.1**). Furthermore, in this model the individual effects of SNVs are not explicitly estimated; instead, their variance is evaluated as a hyper-parameter using restricted maximum-likelihood (REML)<sup>23</sup>, where separate variance terms can be associated with different groups of SNVs falling in distinct categories. In addition to the neutral model above, we utilized two further local background models, including PCAWG-wide randomized datasets as well as our custom randomization correcting for various covariates (see **supplemental section 1.1.a-c**).

We compared several versions of the additive variance model (explained above) in 8 cancer cohorts having a sample size greater than 100. In the first model, we separated the mutations into two categories, corresponding to drivers (from the PCAWG analysis) and *putative passengers* (**Fig. 5ci**). *Putative passengers* were only included in the model if found in at least two samples from a cohort (which can be any combination of observed and simulated samples). Additionally, to maximize the predictive potential of the driver mutations, we used a binary variable which is 1 if any driver mutation is present in a sample as a predictor (details in **supplement section 8.1**). This approach effectively isolates the effect of *putative passengers* in tumors without driver mutations. In this model, we observed an increase in the variance explained from ~49.9% using drivers alone to ~59.4% with *putative passengers* when averaged across all cohorts, with the *putative passenger* contribution significant at FDR<0.1 in all cohorts except kidney-RCC cohort, suggesting that non-neutral effects are present among the *putative passenger* mutations (**Supplement Table 3a**). We further tested a different version of the model in which we split mutations into coding, promoter and other non-coding categories, where the coding mutations are a superset of the PCAWG drivers (**Fig. 5cii**). Here, we observed that the coding mutations accounted for by far the largest overall proportion of the variance (~50.7% averaged across cohorts), while promoters and other non-coding also contributed much lesser, but still significant amounts of extra variance (~1.9% and 6.9% respectively overall, with cohort-specific contributions from each category at FDR<0.1, **Supplement Table 3b**). Although the

total contribution of the promoters is lowest in this model, we calculated the additive variance per SNV by normalizing by the number of SNVs in each category (**Fig. 5ciii**) and found that the normalized variance is substantially higher in promoters than other non-coding, although lower than coding mutations. Further, we tested the sensitivity of our results to the choice of null model by repeating these analyses for two other randomization schemes, and compared the variance on observed and liability scales, with quantitatively similar results (**Supplement Tables 4-7**). We also verified that our model effectively controls for overfitting by observing near zero additive variance when a second randomized sample is substituted for the observed genotypes, and that the sensitivity of the results to changes in the randomization window size is small (**Supplemental Table 10a-b**). To further verify that the model controls for overfitting, we split the data into test and training partitions, and show that the additive variance on the training partition correlates with test predictive accuracy, where we use the Best Linear Unbiased Predictor (BLUP) to cast the model in predictive form (**Supplemental Table 10c and supplemental section 8.2**).

By including a binary predictor for known driver SNVs in the above model, we expect the contribution of the *putative passengers* to be higher among samples without known drivers (as well as all null samples). To confirm that the *putative passengers* were indeed contributing to the discrimination of samples without known drivers, we further calculated the additive variance exclusively for such samples in PCAWG. First, we repeated the analysis of the 8 cohorts above, but with all samples containing known SNV drivers and SNVs falling in known driver elements removed. We observed an average of 12.5% additive variance across cohorts (**Supplement Table 8a**), which was higher than the 9.5% additive variance estimates based on *putative passengers* among all samples (with and without known drivers). This observation is consistent with a more important role for the *putative passengers* among samples without a known driver, since they may have partially redundant effects in the samples harboring known drivers. In a subsequent analysis, we calculated the additive variance after excluding samples with driver SVs and CNAs in addition to samples with known driver SNVs. This analysis was performed for pan-cancer meta-cohort which pools all such samples (**Supplemental Table 8b**). We observed a lower amount of additive variance (6.8%) for the pan-cancer meta cohort, which may be due to tissue-specific effects which are lost at the meta-cohort level. Finally, we estimated the Best Linear Unbiased Predictor (BLUP) for individual cohorts after samples with

predicted SNV, SV and CNA drivers were excluded, including SNVs contained in predicted driver elements (details in **supplement section 8.2**), and used this to derive an estimate of the number of weak drivers among samples lacking predicted PCAWG drivers<sup>22</sup> (**Supplement Table 9**). We conservatively estimate the number of weak drivers by finding the smallest set of SNVs whose additive variance is equal to the additive variance of all the SNVs. A per sample estimate of driver events is then derived by comparing the average number of SNVs from this set in the observed versus random samples. Using this approach, we estimated an average of 8.4 weak drivers per cohort, corresponding to  $\sim 0.81$  weak driver events per tumor. We expect that these estimates are limited by sample size, and thus represent lower bounds.

## **Discussion**


Certain key alterations in the tumor genome, often identified through the detection of strong signals of positive selection on individual variants, have been shown to play a pivotal role in tumor progression. Although a typical tumor has thousands of genomic variants, very few of these ( $\sim 5/\text{tumor}^{24}$ ) are thought to drive tumor growth. The remaining variants, often termed passengers, represent the overwhelming majority of the variants in cancer genomes, and their functional consequences are poorly understood. In this work, we comprehensively characterized *putative passengers* in the PCAWG dataset. Subsequently, we attempted to quantify the cumulative fitness effect of such *putative passengers* on tumor growth through the additive variance model. We note that the above approach relies on applying an accurate background model. However, current null models have inaccuracies due to our incomplete understanding of various mutational processes in cancer. Nonetheless, our additive variance analysis was robust for multiple background models and suggested a potential role of cumulative effect of *putative passengers* on tumor progression. This effort further complements the driver discovery exercise<sup>9</sup> in PCAWG by identifying key alterations beyond strong drivers. Also, our predicted functional impact analyses of *putative passengers* showed that different mutational processes are associated with extensive differences in impact on cellular subsystems, irrespective of whether these cause, are indirectly associated with, or are independent of subclonal fitness differences in an evolving tumor. These observations further motivate follow-up experiments and additional whole-genome analyses to explore the role of *putative passengers* with weak (positive and negative) fitness effects in cancer. In conclusion, our work highlights that an important subset of somatic variants

currently identified as *putative passengers* nonetheless may have biologically and clinically relevant functional roles across a range of cancers.

## **References**


1. Weinstein, J. N. *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* **45**, 1113–20 (2013).
2. Campbell, P. J. *et al.* Pan-cancer analysis of whole genomes. *bioRxiv* 162784 (2017). doi:10.1101/162784
3. Khurana, E. *et al.* Role of non-coding sequence variants in cancer. *Nat. Rev. Genet.* **17**, 93–108 (2016).
4. Vogelstein, B. & Kinzler, K. W. The Path to Cancer — Three Strikes and You’re Out. *N. Engl. J. Med.* **373**, 1895–1898 (2015).
5. Castro-Giner, F., Ratcliffe, P. & Tomlinson, I. The mini-driver model of polygenic cancer evolution. *Nat. Rev. Cancer* **15**, 680–685 (2015).
6. McFarland, C. D., Korolev, K. S., Kryukov, G. V, Sunyaev, S. R. & Mirny, L. A. Impact of deleterious passenger mutations on cancer progression. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 2910–5 (2013).
7. Yung, C. K. *et al.* Large-Scale Uniform Analysis of Cancer Whole Genomes in Multiple Computing Environments. *bioRxiv* 161638 (2017). doi:10.1101/161638
8. Li, Y. *et al.* Patterns of structural variation in human cancer. *bioRxiv* 181339 (2017). doi:10.1101/181339
9. Rheinbay, E. *et al.* Discovery and characterization of coding and non-coding driver mutations in more than 2,500 whole cancer genomes. *bioRxiv* 237313 (2017). doi:10.1101/237313
10. Fonseca, N. A. *et al.* Pan-cancer study of heterogeneous RNA aberrations. *bioRxiv* 183889 (2017). doi:10.1101/183889
11. Fu, Y. *et al.* FunSeq2: A framework for prioritizing noncoding regulatory variants in cancer. *Genome Biol.* **15**, 480 (2014).
12. Ciriello, G. *et al.* Emerging landscape of oncogenic signatures across human cancers. *Nat. Genet.* **45**, 1127–33 (2013).
13. Sudmant, P. H. *et al.* An integrated map of structural variation in 2,504 human genomes. *Nature* **526**, 75–81 (2015).
14. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. *Nat. Rev. Genet.* **15**, 585–598 (2014).
15. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415–21 (2013).
16. Mroz, E. A. & Rocco, J. W. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. *Oral Oncol.* **49**, 211–215 (2013).
17. Lawrence, M. S. *et al.* Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**, 495–501 (2014).
18. Rheinbay, E. *et al.* Recurrent and functional regulatory mutations in breast cancer. *Nature* (2017). doi:10.1038/nature22992

19. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat. Genet.* **42**, 565–9 (2010).
20. International Schizophrenia Consortium, S. M. *et al.* Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–52 (2009).
21. Furlong, L. I. Human diseases through the lens of network biology. *Trends Genet.* **29**, 150–159 (2013).
22. Sabarinathan, R. *et al.* The whole-genome panorama of cancer drivers. *bioRxiv* 190330 (2017). doi:10.1101/190330
23. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
24. Vogelstein, B. & Kinzler, K. W. The Path to Cancer --Three Strikes and You're Out. *N. Engl. J. Med.* **373**, 1895–8 (2015).




**Figure 1: Overall functional impact of PCAWG variants:** **a)** Functional impact distribution in noncoding regions: three peaks correspond to low-, medium- and high-impact variants; **b)** Correlation between the fraction of impactful noncoding SNVs and the total mutational counts for different cancer cohorts. **c)** log ratio of high-impact structural variants(SVs) and SNVs in different cancer cohorts.








**Figure 2: Overall functional burdening of different genomic elements: a)** Percentage of genes in different gene categories (apoptosis, cell cycle, cancer pathway, dna repair, metabolic and essential genes) affected by non-driver LoFs in observed and random model; **b)** Pan-cancer overview of TFs burdening: heatmap of differential burdening of various TFs due to SNVs that induce motif breaking and motif-gaining events in different cohorts compared to the genomic background; **c)** Target genes affected due to motif gain and loss in ETS transcription factor family: genes such as TERT, RP17-731F5.2 and JSRP1 are affected due to gain-of-motif events, whereas ASXL2 and RPS27 are affected due to loss-of-motif events; **d)** q-q plot showing genes such as TERT, PIM1 and BCL2, which are differentially expressed due to gain-of-motif events in ETS TFs; **e)** enrichment of germline and somatic large deletions in coding region and transcription factor binding peaks. Large deletions can engulf or partially delete various genomic elements.





**Figure 4: Correlating functional burdening with subclonal information and patient survival:** **a)** Subclonal ratio (early/late) for different categories of SNVs (coding/non-coding) based on their impact scores. Subclonal ratios for high-impact SNVs occupying distinct gene sets; **b)** Mutant tumor allele heterogeneity difference comparison between high-, medium- and low-impact SNVs for coding(left) and non-coding regions(right); **c)** correlation between mean VAF and GERP score of different categories of variants (driver SNVs, non-driver SNVs in known cancer genes & passenger variants in non-driver genes) on a pan-cancer level; **d)** Survival curves in CLL (*left panel*) and RCC (*right panel*) with 95% confidence intervals, stratified by mean GERP score.



**Figure 5. Conceptual classification of somatic variants based on their functional impact and selection characteristics, and additive effects model:** **a)** Both coding and non-coding variants can be classified as drivers or passengers based on their impact and signatures of positive selection. Among putative passengers, true passengers undergo neutral selection and tend to confer low functional impact. Deleterious passengers (weak and strong) and mini-drivers (weak and strong) represent various categories of higher-impact nominal passenger variants, which may undergo weak negative or positive selection; **b)** *Additive effects model for nominal passengers:* The combined effects of many nominal passengers are modeled using a linear model, which predicts whether a genotype arises from an observed cancer sample or from a null (neutral) model (notation defined in **supplement section 8.1**). The model is fitted by optimizing the hyper-parameter  $\sigma_A^2$ , and a test for significant combined effects of the nominal passengers is made by performing a log-likelihood ratio test against a restricted model which includes only  $\mu$  and  $e$ ; **c)** *Predictive power of known drivers and nominal passengers using the additive effects model:* (i) compares the maximum possible variance which can be explained using known drivers with the performance of the model containing driver and putative passengers; (ii) further breaks this down into a contribution from coding, coding and promoter and all variant; (iii) presents normalized additive variance explained exclusively by putative passengers in coding regions, exclusively by promoters, and exclusively by other non-coding only elements of the genome.